Exploring the trajectory of quality-of-life deterioration associated with capecitabine-induced hand-foot syndrome and the optimal timing for rehabilitation intervention: secondary analysis of a randomized controlled trial
Objective To investigate the dynamic progression and key turning points of quality-of-life (QoL) impairment in patients with capecitabine-induced hand-foot syndrome (HFS) and identify the optimal timing for rehabilitation intervention. Methods This secondary analysis included 234 breast cancer patients receiving capecitabine from a multicenter, double-blind randomized controlled trial. HFS-related QoL (HF-QoL), EORTC QLQ-C30, and QLQ-BR23 were assessed longitudinally. Generalized estimating equations examined HFS grade-by-time interactions, and clinically significant deterioration was defined using the minimum clinically important difference (MCID ≥10 points). Results Significant HFS grade-by-time interactions were observed for HF-QoL (β=1.215, 95% CI = [0.689, 1.741], P < 0.001), QLQ-C30 (β=1.464, 95% CI = [0.820, 2.109], P < 0.001), and QLQ-BR23 (β=0.451, 95% CI = [0.148,0.753], P = 0.004), indicating accelerated QoL deterioration with increasing HFS severity. The proportion of patients with clinically significant HF-QoL deterioration increased sharply from Grade 1 to Grade 2 (18.9% vs. 41.9%; OR = 3.053, P = 0.010). Conclusion HFS severity and QoL deterioration show divergent trajectories; Grade 2 may represent a critical threshold at which QoL impairment crosses the threshold of clinical significance; progression from HFS Grade 1 to Grade 2 may be a potential time point for validation in future prospective rehabilitation intervention studies.
Authors
- Yifan Lin
- Jie Jia
- Jie Zhang
- Weilin Yin
- Yujing Wang
Institutions
- Fujian Medical University (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-11-12
- DOI
- https://doi.org/10.3389/fonc.2026.1988890
- Primary Topic
- Chemotherapy-related skin toxicity
- Type
- article
- Field-Weighted Citation Impact
- 0.00